SCHEMBL2575212

SCHEMBL2575212

CCOC(=O)c1cc[nH]c1N=C=S

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.48
TSHR P16473 1/20 0.45
NUDT1 P36639 1/20 0.45
GRM6 O15303 1/20 0.41
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 3/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
MAPT P10636 5/20 0.38
CLEC4M Q9H2X3 1/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2579474 0.93 KMT2A (0.43) KMT2ATSHRNUDT1GRM6ALDH1A1
SCHEMBL9921991 0.80 KMT2A (0.51) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL9918656 0.78 KMT2A (0.49) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL31575794 0.77 KMT2A (0.46) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL2564768 0.77 GRM6 (0.41) KMT2ATSHRNUDT1GRM6ALDH1A1
SCHEMBL1156163 0.74 KMT2A (0.58) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL1457077 0.73 TSHR (0.61) KMT2ATSHRGRM6ALDH1A1KDM4E
SCHEMBL2069470 0.73 KMT2A (0.56) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL163150 0.73 KMT2A (0.56) KMT2ATSHRNUDT1ALDH1A1KDM4E
SCHEMBL3267220 0.73 KMT2A (0.56) KMT2ATSHRNUDT1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES KMT2A 2107/4885TSHR 4543/4885NUDT1 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.